Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) has received an average rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One research analyst ...

A study found that the higher the degree of fat accumulation in the muscle, the lower the effectiveness of breast cancer ...

He had a history of atrial fibrillation (AF) that initially occurred 2 years before in the context of streptococcal ...